PREMARIN® VAGINAL CREAM Adverse Reactions

(conjugated estrogens)

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions (5.2)]
Malignant Neoplasms [see Boxed Warning, Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 12-week, randomized, double-blind, placebo-controlled trial of PREMARIN Vaginal Cream (PVC), a total of 423 postmenopausal women received at least 1 dose of study medication and were included in all safety analyses: 143 women in the PVC-21/7 treatment group (0.5 g PVC daily for 21 days, then 7 days off), 72 women in the matching placebo treatment group; 140 women in the PVC-2×/wk treatment group (0.5 g PVC twice weekly), 68 women in the matching placebo treatment group. A 40-week, open-label extension followed, in which a total of 394 women received treatment with PVC, including those subjects randomized at baseline to placebo. In this study, the most common adverse reactions ≥ 1 percent in the double blind phase are shown below (Table 1) [see Clinical Studies (14.1)].

Table 1: Number (%) of Patients Reporting Treatment Emergent Adverse Reactions ≥ 1 Percent Only
Treatment
Body System*/Adverse ReactionPVC 21/7

N=143
Placebo 21/7

N=72
PVC 2×/week

N=140
Placebo 2×/week
N=68
Number (%) of Patients with Adverse Reaction
*
Body system totals are not necessarily the sum of individual adverse events, since a patient may report two or more different adverse reactions in the same body system.

Body As A Whole

Abdominal Pain

1 (0.7)

1 (1.4)

0

1 (1.5)

Headache

5 (3.5)

1 (1.4)

3 (2.1)

1 (1.5)

Moniliasis

2 (1.4)

1 (1.4)

1 (0.7)

0

Pain

2 (1.4)

0

1 (0.7)

0

Pelvic Pain

4 (2.8)

2 (2.8)

4 (2.9)

0

Cardiovascular System

Migraine

0

0

0

1 (1.5)

Vasodilation

3 (2.1)

2 (2.8)

2 (1.4)

0

Musculoskeletal System

Muscle Cramp

2 (1.4)

0

0

0

Nervous System

Dizziness

1 (0.7)

0

0

1 (1.5)

Skin and Appendages

Acne

0

0

2 (1.4)

0

Erythema

0

1 (1.4)

0

0

Pruritus

2 (1.4)

1 (1.4)

1 (0.7)

0

Urogenital System

Breast Enlargement

1 (0.7)

1 (1.4)

0

0

Breast Pain

7 (4.9)

0

3 (2.1)

0

Dysuria

2 (1.4)

0

0

0

Leukorrhea

3 (2.1)

1 (1.4)

4 (2.9)

5 (7.4)

Metrorrhagia

0

0

0

2 (2.9)

Urinary Frequency

0

1 (1.4)

0

0

Urinary Tract Infection

0

1 (1.4)

0

0

Urinary Urgency

1 (0.7)

1 (1.4)

0

0

Vaginal Hemorrhage

2 (1.4)

0

1 (0.7)

1 (1.5)

Vaginal Moniliasis

2 (1.4)

0

0

0

Vaginitis

2 (1.4)

1 (1.4)

3 (2.1)

3 (4.4)

Vulvovaginal Disorder

4 (2.8)

0

3 (2.1)

2 (2.9)

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of PREMARIN Vaginal Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary System

Abnormal uterine bleeding or spotting, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis (including vaginal candidiasis), change in cervical secretion, cystitis-like syndrome, application site reactions of vulvovaginal discomfort, (including burning, irritation, and genital pruritus), endometrial hyperplasia, endometrial cancer, precocious puberty, leukorrhea.

Breasts

Tenderness, enlargement, pain, discharge, fibrocystic breast changes, breast cancer, gynecomastia in males.

Cardiovascular

Deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, increase in blood pressure.

Gastrointestinal

Nausea, vomiting, abdominal cramps, bloating, increased incidence of gallbladder disease.

Skin

Chloasma that may persist when drug is discontinued, loss of scalp hair, hirsutism, rash.

Eyes

Retinal vascular thrombosis, intolerance to contact lenses.

Central Nervous System

Headache, migraine, dizziness, mental depression, nervousness, mood disturbances, irritability, dementia.

Miscellaneous

Increase or decrease in weight, glucose intolerance, edema, arthralgias, leg cramps, changes in libido, urticaria, exacerbation of asthma, increased triglycerides, hypersensitivity.

Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.

Find PREMARIN® VAGINAL CREAM medical information:

Find PREMARIN® VAGINAL CREAM medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PREMARIN® VAGINAL CREAM Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions (5.2)]
Malignant Neoplasms [see Boxed Warning, Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 12-week, randomized, double-blind, placebo-controlled trial of PREMARIN Vaginal Cream (PVC), a total of 423 postmenopausal women received at least 1 dose of study medication and were included in all safety analyses: 143 women in the PVC-21/7 treatment group (0.5 g PVC daily for 21 days, then 7 days off), 72 women in the matching placebo treatment group; 140 women in the PVC-2×/wk treatment group (0.5 g PVC twice weekly), 68 women in the matching placebo treatment group. A 40-week, open-label extension followed, in which a total of 394 women received treatment with PVC, including those subjects randomized at baseline to placebo. In this study, the most common adverse reactions ≥ 1 percent in the double blind phase are shown below (Table 1) [see Clinical Studies (14.1)].

Table 1: Number (%) of Patients Reporting Treatment Emergent Adverse Reactions ≥ 1 Percent Only
Treatment
Body System*/Adverse ReactionPVC 21/7

N=143
Placebo 21/7

N=72
PVC 2×/week

N=140
Placebo 2×/week
N=68
Number (%) of Patients with Adverse Reaction
*
Body system totals are not necessarily the sum of individual adverse events, since a patient may report two or more different adverse reactions in the same body system.

Body As A Whole

Abdominal Pain

1 (0.7)

1 (1.4)

0

1 (1.5)

Headache

5 (3.5)

1 (1.4)

3 (2.1)

1 (1.5)

Moniliasis

2 (1.4)

1 (1.4)

1 (0.7)

0

Pain

2 (1.4)

0

1 (0.7)

0

Pelvic Pain

4 (2.8)

2 (2.8)

4 (2.9)

0

Cardiovascular System

Migraine

0

0

0

1 (1.5)

Vasodilation

3 (2.1)

2 (2.8)

2 (1.4)

0

Musculoskeletal System

Muscle Cramp

2 (1.4)

0

0

0

Nervous System

Dizziness

1 (0.7)

0

0

1 (1.5)

Skin and Appendages

Acne

0

0

2 (1.4)

0

Erythema

0

1 (1.4)

0

0

Pruritus

2 (1.4)

1 (1.4)

1 (0.7)

0

Urogenital System

Breast Enlargement

1 (0.7)

1 (1.4)

0

0

Breast Pain

7 (4.9)

0

3 (2.1)

0

Dysuria

2 (1.4)

0

0

0

Leukorrhea

3 (2.1)

1 (1.4)

4 (2.9)

5 (7.4)

Metrorrhagia

0

0

0

2 (2.9)

Urinary Frequency

0

1 (1.4)

0

0

Urinary Tract Infection

0

1 (1.4)

0

0

Urinary Urgency

1 (0.7)

1 (1.4)

0

0

Vaginal Hemorrhage

2 (1.4)

0

1 (0.7)

1 (1.5)

Vaginal Moniliasis

2 (1.4)

0

0

0

Vaginitis

2 (1.4)

1 (1.4)

3 (2.1)

3 (4.4)

Vulvovaginal Disorder

4 (2.8)

0

3 (2.1)

2 (2.9)

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of PREMARIN Vaginal Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary System

Abnormal uterine bleeding or spotting, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis (including vaginal candidiasis), change in cervical secretion, cystitis-like syndrome, application site reactions of vulvovaginal discomfort, (including burning, irritation, and genital pruritus), endometrial hyperplasia, endometrial cancer, precocious puberty, leukorrhea.

Breasts

Tenderness, enlargement, pain, discharge, fibrocystic breast changes, breast cancer, gynecomastia in males.

Cardiovascular

Deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, increase in blood pressure.

Gastrointestinal

Nausea, vomiting, abdominal cramps, bloating, increased incidence of gallbladder disease.

Skin

Chloasma that may persist when drug is discontinued, loss of scalp hair, hirsutism, rash.

Eyes

Retinal vascular thrombosis, intolerance to contact lenses.

Central Nervous System

Headache, migraine, dizziness, mental depression, nervousness, mood disturbances, irritability, dementia.

Miscellaneous

Increase or decrease in weight, glucose intolerance, edema, arthralgias, leg cramps, changes in libido, urticaria, exacerbation of asthma, increased triglycerides, hypersensitivity.

Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.